Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 25
Filter
Add more filters










Publication year range
1.
Peptides ; 48: 27-35, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23911665

ABSTRACT

The pharmacological activity of the novel neuropeptide S (NPS) receptor (NPSR) ligands QA1 and PI1 was investigated. In vitro QA1 and PI1 were tested in calcium mobilization studies performed in HEK293 cells expressing the recombinant mouse (HEK293mNPSR) and human (HEK293hNPSRIle107 and HEK293hNPSRAsn107) NPSR receptors. In vivo the compounds were studied in mouse righting reflex (RR) and locomotor activity (LA) tests. NPS caused a concentration dependent mobilization of intracellular calcium in the three cell lines with high potency (pEC50 8.73-9.14). In inhibition response curve and Schild protocol experiments the effects of NPS were antagonized by QA1 and PI1. QA1 displayed high potency (pKB 9.60-9.82) behaving as a insurmountable antagonist. However in coinjection experiments QA1 produced a rightward swift of the concentration response curve to NPS without modifying its maximal effects; this suggests that QA1 is actually a slow dissociating competitive antagonist. PI1 displayed a competitive type of antagonism and lower values of potencies (pA2 7.74-8.45). In vivo in mice NPS (0.1 nmol, i.c.v.) elicited arousal promoting action in the RR assay and stimulant effects in the LA test. QA1 (30 mgkg(-1)) was able to partially counteract the arousal promoting NPS effects, while PI1 was inactive in the RR test. In the LA test QA1 and PI1 only poorly blocked the NPS stimulant action. The present data demonstrated that QA1 and PI1 act as potent NPSR antagonists in vitro, however their usefulness for in vivo investigations in mice seems limited probably by pharmacokinetic reasons.


Subject(s)
Amides/administration & dosage , Calcium/metabolism , Imidazoles/administration & dosage , Indoles/administration & dosage , Ligands , Neuropeptides/genetics , Quinolones/administration & dosage , Receptors, Neuropeptide/genetics , Animals , Calcium/physiology , Gene Expression Regulation/drug effects , HEK293 Cells , Humans , Mice , Motor Activity/drug effects , Neuropeptides/chemistry , Receptors, Neuropeptide/metabolism , Reflex, Righting/drug effects
2.
Neuropeptides ; 36(2-3): 72-6, 2002.
Article in English | MEDLINE | ID: mdl-12359498

ABSTRACT

Transgenic mice lacking expression of the OFQ/N precursor protein have provided exciting insights in the physiological functions of this neuropeptide system. While injection of OFQ/N or selective synthetic agonists produces anxiolytic effects in rodents, OFQ/N knockout mice display increased anxiety and impaired adaptation to repeated stress. On the other hand, mice lacking the cognate OFQ/N receptor, ORL1, show improved spatial attention and memory but appear to have normal anxiety and stress behavior. Availability of a selective small molecule OFQ/N antagonist might help clarify this discrepancy.


Subject(s)
Mice, Knockout/physiology , Opioid Peptides/genetics , Stress, Psychological/genetics , Animals , Learning/physiology , Memory/physiology , Mice , Mice, Knockout/genetics , Opioid Peptides/physiology , Stress, Psychological/psychology , Nociceptin
3.
Trends Neurosci ; 24(4): 230-7, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11250008

ABSTRACT

The "orphan" G-protein-coupled receptors (GPCRs) are cloned GPCRs that bind unknown ligands. Since 1995, nineteen orphan GPCRs have been used as targets to identify and isolate their natural ligands via the application of the "orphan receptor strategy". These ligands are peptides, lipids or biogenic amines, and act as transmitter molecules. One nucleotide-sugar derivative and six peptides or peptide families identified through this strategy are novel and have already enriched our understanding of various brain functions.


Subject(s)
GTP-Binding Proteins/metabolism , Ligands , Neurotransmitter Agents/metabolism , Receptors, G-Protein-Coupled , Second Messenger Systems/physiology , Animals , Humans , Immediate-Early Proteins/drug effects , Immediate-Early Proteins/physiology , Neuropeptides/drug effects , Neuropeptides/metabolism , Neuropeptides/pharmacology , Neurotransmitter Agents/pharmacology , Receptors, Cell Surface/drug effects , Receptors, Cell Surface/metabolism , Receptors, Lysophospholipid , Second Messenger Systems/drug effects
4.
Mol Pharmacol ; 58(6): 1601-8, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11093801

ABSTRACT

The cysteinyl leukotrienes (CysLTs) are potent biological mediators in the pathophysiology of inflammatory diseases, in particular of airway obstruction in asthma. Pharmacological studies have suggested the existence of at least two types of CysLT receptors, designated CysLT(1) and CysLT(2). The CysLT(1) receptor has been cloned recently. Here we report the molecular cloning, expression, localization, and functional characterization of a human G protein-coupled receptor that has the expected characteristics of a CysLT(2) receptor. This new receptor is selectively activated by nanomolar concentrations of CysLTs with a rank order potency of LTC(4) = LTD(4) >> LTE(4). The leukotriene analog BAY u9773, reported to be a dual CysLT(1)/CysLT(2) antagonist, was found to be an antagonist at CysLT(1) sites but acted as a partial agonist at this new receptor. The structurally different CysLT(1) receptor-selective antagonists zafirlukast, montelukast, and MK-571 did not inhibit the agonist-mediated calcium mobilization of CysLT(2) receptors at physiological concentrations. Localization studies indicate highest expression of CysLT(2) receptors in adrenal glands, heart, and placenta; moderate levels in spleen, peripheral blood leukocytes, and lymph nodes; and low levels in the central nervous system and pituitary. The human CysLT(2) receptor gene is located on chromosome 13q14.12-21.1. The new receptor exhibits all characteristics of the thus far poorly defined CysLT(2) receptor. Moreover, we have identified BAY u9773 as a CysLT(2) selective agonist, which could prove to be of immediate use in understanding the functional roles of the CysLT(2) receptor.


Subject(s)
Membrane Proteins , Receptors, Leukotriene/genetics , SRS-A/analogs & derivatives , Amino Acid Sequence , Base Sequence , Binding, Competitive , Cloning, Molecular , Dose-Response Relationship, Drug , Humans , Leukotriene Antagonists/pharmacology , Leukotriene D4/pharmacology , Molecular Sequence Data , Receptors, Leukotriene/agonists , SRS-A/pharmacology , Tissue Distribution , Tritium
5.
Peptides ; 21(7): 901-6, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10998523

ABSTRACT

Like other neuropeptides, orphanin FQ/nociceptin (OFQ/N) is encoded by a larger precursor protein. The cDNA for the OFQ/N precursor has been cloned from human, rat, mouse and bovine tissue demonstrating that this peptidergic system serves important functions that have been conserved during evolution. The structural organization of the precursor protein is similar to opioid peptide precursors, supporting the view of a common origin for the opioid systems and the OFQ/N system. In addition to OFQ/N, the precursor may encode two other biologically active peptides. Anatomic studies have revealed high levels of expression of the OFQ/N messenger RNA in brain structures involved in sensory, emotional and cognitive processing. In particular, high levels of OFQ/N mRNA were detected in the limbic system, underlining the stress attenuating activities that have been described as an important function of OFQ/N. Recently, mutant mice have been generated that lack the precursor protein of OFQ/N to further define the physiological functions of the OFQ/N system. The OFQ/N-deficient mice are characterized by an increased sensitivity to stressful stimuli and a lack of habituation to chronic and repeated stress. This review will summarize recent findings on the molecular biology of the OFQ/N precursor and relate it to possible physiological functions of this newly discovered neuropeptide system.


Subject(s)
Opioid Peptides/chemistry , Opioid Peptides/genetics , Amino Acid Sequence , Animals , Cell Line , Cloning, Molecular , DNA, Complementary/metabolism , Humans , Mice , Mice, Knockout , Molecular Sequence Data , Opioid Peptides/biosynthesis , Peptides/chemistry , Peptides/genetics , RNA, Messenger/biosynthesis , Sequence Homology, Amino Acid , Tissue Distribution , Vasodilator Agents/chemistry , Nociceptin
6.
J Neurosci ; 20(11): 4037-49, 2000 Jun 01.
Article in English | MEDLINE | ID: mdl-10818139

ABSTRACT

We have used site-directed mutagenesis in conjunction with homologous recombination to generate two mouse lines carrying point mutations in the glycine binding site of the NMDAR1 subunit (Grin1). Glycine concentration-response curves from acutely dissociated hippocampal neurons revealed a 5- and 86-fold reduction in receptor glycine affinity in mice carrying Grin1(D481N) and Grin1(K483Q) mutations, respectively, whereas receptor glutamate affinity remained unaffected. Homozygous mutant Grin1(D481N) animals are viable and fertile and appear to develop normally. However, homozygous mutant Grin1(K483Q) animals are significantly lighter at birth, do not feed, and die within a few days. No gross abnormalities in CNS anatomy were detected in either Grin1(D481N) or Grin1(K483Q) mice. Interestingly, in situ hybridization and Western blot analysis revealed changes in the expression levels of NMDA receptor subunits in Grin1(D481N) mice relative to wild type that may represent a compensatory response to the reduction in receptor glycine affinity. Grin1(D481N) mice exhibited deficits in hippocampal theta burst-induced long-term potentiation (LTP) and spatial learning and also a reduction in sensitivity to NMDA-induced seizures relative to wild-type controls, consistent with a reduced activation of NMDA receptors. Mutant mice exhibited normal prepulse inhibition but showed increased startle reactivity. Preliminary analysis indicated that the mice exhibit a decreased natural aversion to an exposed environment. The lethal phenotype of Grin1(K483Q) animals confirms the critical role of NMDA receptor activation in neonatal survival. A milder reduction in receptor glycine affinity results in an impairment of LTP and spatial learning and alterations in anxiety-related behavior, providing further evidence for the role of NMDA receptor activation in these processes.


Subject(s)
Glycine/physiology , Point Mutation/physiology , Receptors, Glycine/genetics , Receptors, Glycine/physiology , Receptors, N-Methyl-D-Aspartate/genetics , Receptors, N-Methyl-D-Aspartate/physiology , Animals , Autoradiography , Behavior, Animal/physiology , Blotting, Southern , Blotting, Western , Calcium/physiology , Cerebral Cortex/cytology , Cerebral Cortex/metabolism , Gene Targeting , Hippocampus/cytology , Hippocampus/metabolism , Homozygote , Image Interpretation, Computer-Assisted , In Situ Hybridization , Long-Term Potentiation/physiology , Mice , Patch-Clamp Techniques , Point Mutation/genetics , Reflex, Startle/physiology , Reverse Transcriptase Polymerase Chain Reaction , Seizures/chemically induced , Seizures/genetics , Seizures/physiopathology
7.
Brain Res ; 848(1-2): 63-5, 1999 Nov 27.
Article in English | MEDLINE | ID: mdl-10612697

ABSTRACT

By the beginning of the next millennium, the search for the natural ligands of the orphan G-protein-coupled receptors will lead to the discovery of so many new neuropeptides that it may well double their present number. This bounty of new tools will direct us to new insights in brain function and to better understanding of brain disorders. It is expected that the novel neuropeptides will have a particular impact on molecular psychiatry. In view of their potential, the novel neuropeptides should also become the focus of drug discovery programs. It is hoped that these programs will be initiated at an early stage, when understanding of novel neuropeptide function has not necessarily been reached, to allow for the design of neuropeptide chemical surrogates that are crucial to the study of the novel neuropeptide system and may serendipitously develop into highly successful drugs.


Subject(s)
GTP-Binding Proteins/metabolism , Neuropeptides/metabolism , Receptors, Cell Surface/metabolism , Drug Design , Humans
8.
Proc Natl Acad Sci U S A ; 96(18): 10444-9, 1999 Aug 31.
Article in English | MEDLINE | ID: mdl-10468628

ABSTRACT

The neuropeptide orphanin FQ (also known as nociceptin; OFQ/N) has been implicated in modulating stress-related behavior. OFQ/N was demonstrated to reverse stress-induced analgesia and possess anxiolytic-like activity after central administration. To further study physiological functions of OFQ/N, we have generated OFQ/N-deficient mice by targeted disruption of the OFQ/N gene. Homozygous mice display increased anxiety-like behavior when exposed to a novel and threatening environment. OFQ/N-null mice show elevated basal pain threshold but develop normal stress-induced analgesia. Interestingly, these mice show impaired adaptation to repeated stress when compared with wild-type mice, whereas their performance in spatial learning remained unaffected. Basal and poststress plasma corticosterone levels were found to be elevated in OFQ/N-deficient animals. Thus, OFQ/N appears to be crucially involved in the neurobiological regulation of stress-coping behavior and fear.


Subject(s)
Maze Learning , Motor Activity , Opioid Peptides/genetics , Opioid Peptides/physiology , Pain/physiopathology , Stress, Psychological/genetics , Analgesia , Animals , Anxiety/genetics , Anxiety/physiopathology , Corticosterone/blood , Genetic Predisposition to Disease , Heterozygote , Homozygote , Mice , Mice, Knockout , Opioid Peptides/deficiency , Perception , Receptors, Opioid/physiology , Space Perception , Stress, Psychological/physiopathology , Nociceptin Receptor , Nociceptin
9.
Results Probl Cell Differ ; 26: 193-214, 1999.
Article in English | MEDLINE | ID: mdl-10453465

ABSTRACT

The cloning of numerous orphan members from the supergene family of G protein-coupled receptors implies the existence of many as yet undiscovered neurotransmitters and neuropeptides. Recently, new technologies were developed to isolate natural ligands for orphan receptors, using the receptor as a biological sensor during the purification process. This manuscript will present the concept and technology of an approach which starts from a cloned receptor to ultimately describe the physiological functions of the transmitter system. This strategy inverts the classical order of biomedical research and was thus termed "reverse physiology". The first natural ligand isolated by this strategy is a peptide with significant similarity to the opioid peptides and has been named orphanin FQ or nociceptin (OFQ/NOC). Evidence for characterizing OFQ/NOC as a genuine neuropeptide will be reviewed. OFQ/NOC is biosynthetically derived from a larger precursor protein which may encode additional bioactive peptides. Since its discovery, a large number of studies have described numerous physiological functions of OFQ/NOC. Because of its relation to the opioid system, much attention has been focused on the involvement of OFQ/NOC in nociception, sometimes with controversial results. However, the pharmacological profile of the OFQ/NOC system suggests a clear separation from the opioids. The discovery of OFQ/NOC and the subsequent analyses of its physiological functions is an example which has already been followed by the identification of two other novel neuropeptides. The orphan receptor strategy holds a lot of promises for the postgenomic era, helping to fill the vast amount of sequence data with life.


Subject(s)
Molecular Biology/methods , Opioid Peptides , Physiology/methods , Receptors, Opioid , Amino Acid Sequence , Animals , Behavior, Animal , Molecular Sequence Data , Neurotransmitter Agents , Signal Transduction , Nociceptin
10.
Mol Pharmacol ; 53(4): 772-7, 1998 Apr.
Article in English | MEDLINE | ID: mdl-9547370

ABSTRACT

Although much has been learned about the mechanisms of ligand selectivity between different opioid receptor subtypes, little is known about the common opioid binding pocket shared by all opioid receptors. The recently discovered orphanin system offers a good opportunity to study the mechanisms involved in the binding of opioid versus nonopioid ligands. In the current study, we adopt a "gain of function" approach aimed at shifting the binding profile of the orphanin FQ receptor toward that of the opioid receptors. After two rounds of mutagenesis, several orphanin FQ receptor mutants can be labeled with the opiate alkaloid [3H]naltrindole and show greatly increased affinities toward the opiate antagonists naltrexone, nor-binaltrophine HCl, and (-)-bremazocine. These orphanin FQ receptor mutants also display stereospecificity similar to that of opioid receptors. Furthermore, the orphanin FQ receptor mutant that has the best affinities toward the opioid alkaloids shows, in the presence of GTP and high salt concentration, an affinity-shift profile similar to that of the delta receptor. Most strikingly, the same mutant exhibits naltrindole-sensitive etorphine-stimulated [35S]guanosine-5'-O-(3-thio)triphosphate binding, whereas the effect of etorphine on GTP binding cannot be inhibited by naltrindole in the wild-type receptor. Our results indicate that 1) several residues in the orphanin FQ receptor are critical to its selectivity against the opiate alkaloids, particularly antagonists; and 2) mutating these residues to those of the opioid receptor at the corresponding position preserves the agonist/antagonist nature of opiate alkaloids as they interact with the mutant receptor. It is reasonable to hypothesize that the corresponding residues in the opioid receptors may form a functional common binding pocket for opiate alkaloids. These findings may be helpful to medicinal chemists in designing ligands for the orphanin FQ receptor based on the structure of the opiate alkaloids.


Subject(s)
Mutagenesis, Site-Directed , Opioid Peptides/metabolism , Receptors, Opioid/genetics , Receptors, Opioid/metabolism , Amino Acid Substitution/genetics , Animals , Binding Sites/drug effects , Binding Sites/genetics , Enkephalins/metabolism , Enkephalins/pharmacology , Ligands , Protein Precursors/metabolism , Protein Precursors/pharmacology , Rats , Receptors, Opioid/agonists , Nociceptin Receptor , Nociceptin
11.
J Biol Chem ; 273(3): 1490-5, 1998 Jan 16.
Article in English | MEDLINE | ID: mdl-9430687

ABSTRACT

Strict pharmacological selectivity in families of structurally related ligands and receptors may result from a key process in evolution aiming at increasing diversity in neurotransmission. An intriguing example of such exclusive specificity can be found in the newly discovered orphanin FQ (OFQ) system when it is compared with the opioid system. Both OFQ and its receptor share a high degree of sequence similarity to the opioid peptides and their corresponding receptors, respectively. However, OFQ does not activate opioid receptors, nor do the opioid peptides elicit biological activity at the OFQ receptor. We have therefore investigated the basis for the inherent selectivity of the primary structures of OFQ and dynorphin A, its closest counterpart. A series of truncated and/or chimeric peptides led to the conclusion that both peptides contain domains which establish their pharmacological selectivity. In the OFQ molecule we could delineate a domain that prevents its ability to activate the kappa-opioid receptor by apparently repelling its binding. In both peptides the selectivity-generating domains are composed of single residues in key positions together with short stretches of amino acids which do not overlap. To prove this concept, we designed a universal agonist and found it active at both the OFQ receptor and the kappa-opioid receptor. Our observations suggest that a coordinated mechanism of evolution has separated the orphanin FQ system from the opioid system.


Subject(s)
Dynorphins/chemistry , Opioid Peptides/chemistry , Receptors, Opioid/agonists , Amino Acid Sequence , Animals , CHO Cells , Cricetinae , Dynorphins/metabolism , Molecular Sequence Data , Opioid Peptides/metabolism , Rats , Receptors, Opioid/metabolism , Receptors, Opioid, delta/metabolism , Receptors, Opioid, kappa/metabolism , Receptors, Opioid, mu/metabolism , Nociceptin Receptor , Nociceptin
12.
Mol Pharmacol ; 51(5): 816-24, 1997 May.
Article in English | MEDLINE | ID: mdl-9145920

ABSTRACT

The heptadecapeptide orphanin FQ (OFQ) has been identified as the endogenous ligand for a G protein-coupled receptor (OFQ-R), which, despite its high degree of sequence similarity to opioid receptors, fails to bind opioid ligands. We developed two radioligands for the OFQ-R: a tritiated native OFQ peptide ([3H]OFQ) and a radioiodinated form in which Leu14 was substituted by tyrosine (125I-Tyr14-OFQ). Their binding properties were examined in human embryonic kidney (HEK) 293 and Chinese hamster ovary (CHO) cells heterologously expressing the OFQ-R at different levels (HEK 293 expressed 40-fold more OFQ-R than did CHO). Both ligands exhibited rapid, monophasic association kinetics in each cell line. Dissociation of both ligands from OFQ-R expressed in HEK 293 cells was biphasic, whereas dissociation of 125I-Tyr14-OFQ from OFQ-R expressed in CHO cells was monophasic and slow. Saturation binding analysis revealed two affinity states in HEK 293 cells with binding parameters in accord with those determined kinetically. In CHO cells, 125I-Tyr14-OFQ detected a single affinity state with an intermediate Kd value of 54 pM. Optimal binding of the radioligands required 1-5 mM MgCl2, whereas millimolar concentrations of ZnCl2, CaCl2, MnCl2, and NaCl reduced specific binding of both ligands. A nonhydrolyzable GTP analog [guanosine-5'-(beta,gamma-imido)triphosphate] reduced the affinity of both OFQ ligands to their receptor without significant changes in the total binding capacity, indicating functional interactions between the OFQ-R and G proteins. In rat brain membranes, specific, saturable binding of 125I-Tyr14-OFQ was demonstrated to be pharmacologically identical to the heterologously expressed OFQ-R. Taken together, these results indicate that 125I-Tyr14-OFQ and [3H]OFQ exhibit virtually identical characteristics and are suitable for the pharmacological analysis of the OFQ-R.


Subject(s)
Guanine Nucleotides/pharmacology , Opioid Peptides/metabolism , Receptors, Opioid/metabolism , Animals , CHO Cells , Cations , Cell Line , Cricetinae , Humans , Iodine Radioisotopes , Kinetics , Opioid Peptides/chemistry , Radioligand Assay , Rats , Tritium , Nociceptin Receptor , Nociceptin
13.
Proc Natl Acad Sci U S A ; 94(26): 14854-8, 1997 Dec 23.
Article in English | MEDLINE | ID: mdl-9405703

ABSTRACT

Orphanin FQ (OFQ, Nociceptin) is a recently discovered 17-amino acid neuropeptide that is structurally related to the opioid peptides but does not bind opioid receptors. OFQ has been proposed to act as an anti-opioid peptide, but its widespread sites of action in the brain suggest that it may have more general functions. Here we show that OFQ plays an important role in higher brain functions because it can act as an anxiolytic to attenuate the behavioral inhibition of animals acutely exposed to stressful/anxiogenic environmental conditions. OFQ anxiolytic-like effects were consistent across several behavioral paradigms generating different types of anxiety states in animals (light-dark preference, elevated plus-maze, exploratory behavior of an unfamiliar environment, pharmacological anxiogenesis, operant conflict) and were observed at low nonsedating doses (0.1-3 nmol, intracerebroventricular). Like conventional anxiolytics, OFQ interfered with regular sensorimotor function at high doses (>3 nmol). Our results show that an important role of OFQ is to act as an endogenous regulator of acute anxiety responses. OFQ, probably in concert with other major neuropeptides, exerts a modulatory role on the central integration of stressful stimuli and, thereby, may modulate anxiety states generated by acute stress.


Subject(s)
Anxiety/physiopathology , Behavior, Animal/physiology , Opioid Peptides/physiology , Receptors, Opioid/physiology , Stress, Physiological/physiopathology , Animals , Male , Mice , Mice, Inbred BALB C , Opioid Peptides/pharmacology , Receptors, Opioid/agonists , Nociceptin
14.
J Biol Chem ; 271(50): 32016-20, 1996 Dec 13.
Article in English | MEDLINE | ID: mdl-8943250

ABSTRACT

It is unclear how receptor/ligand families that are evolutionarily closely related achieve functional separation. To address this question, we focus here on the newly discovered Orphanin FQ, a peptide homologous to the opioid peptide Dynorphin, and its receptor, the Orphanin FQ receptor, which is highly homologous to the opioid receptors. In spite of this high degree of homology in terms of both ligands and receptors, there is little direct cross-talk between the Orphanin FQ system and the endogenous opioid system. Thus, the opioid peptides show either relatively low affinity or no affinity toward the Orphanin FQ receptor; conversely, Orphanin FQ has no affinity toward any of the opioid receptors. We sought to investigate the molecular basis of such discrimination by attempting to reverse it and endowing the Orphanin FQ receptor with the ability to bind opioids. We report that by mutating as few as four amino acids, we can produce a receptor that recognizes pro-Dynorphin products with very high affinity and yet still binds Orphanin FQ as well as the wild-type receptor. This suggests that the Orphanin FQ receptor has developed features that specifically exclude the opioids and that these features are distinct from those required for the high affinity binding of its own endogenous ligand.


Subject(s)
Point Mutation , Receptors, Opioid/genetics , Analgesics/metabolism , Animals , Benzomorphans/metabolism , Dynorphins/metabolism , Models, Molecular , Naltrexone/analogs & derivatives , Naltrexone/metabolism , Narcotic Antagonists/metabolism , Rats , Receptors, Opioid/metabolism , Nociceptin Receptor
15.
J Neurosci ; 16(21): 6657-64, 1996 Nov 01.
Article in English | MEDLINE | ID: mdl-8824306

ABSTRACT

Orphanin FQ (OFQ) has recently been reported to be an endogenous ligand for the opioid-like LC132 receptor. The effect of OFQ on high voltage-gated calcium channels (VGCCs) was examined in freshly dissociated rat pyramidal neurons using the whole-cell configuration of the patch-clamp technique. High-threshold Ba2+ currents were reversibly inhibited by OFQ. The depression of the currents was associated with a slowed rate of activation and a change in the activation I-V relationship at step potentials higher than +30 mV. In concentration-response experiments, a mean (+/-SEM) pEC50 value of 7.0 +/- 0.07 and a Hill coefficient of 1.5 +/- 0.08 (n = 5) were obtained. The near-maximum inhibition of the Ba2+ currents by OFQ (1 microM) amounted to 31 +/- 2.2% of control (n = 15). Opioid receptors could not account for the effects of OFQ on VGCCs, because naloxone, a broad spectrum mu-, delta-, and kappa-receptor antagonist, did not reduce the effectiveness of OFQ. When GTP-gamma-S was included in the pipette, the depression of the currents by OFQ was irreversible, whereas currents from neurons preincubated with pertussis toxin were not inhibited by OFQ, consistent with the involvement of a PTX-sensitive G-protein. When selective blockers of VGCCs were used, it was demonstrated that all subtypes of VGCCs were affected by OFQ. In conclusion, the effect of OFQ on VGCCs expressed in hippocampal CA3 and CA1 neurons may play an important role in the regulation of hippocampal cell excitability and neurotransmitter release.


Subject(s)
Calcium Channels/drug effects , Ion Channel Gating/drug effects , Opioid Peptides/pharmacology , Pyramidal Cells/chemistry , Animals , Barium/pharmacokinetics , Biological Transport/physiology , Calcium Channel Blockers/pharmacology , Cells, Cultured/chemistry , Cells, Cultured/drug effects , Dose-Response Relationship, Drug , Electric Stimulation , GTP-Binding Proteins/physiology , Guanosine 5'-O-(3-Thiotriphosphate)/pharmacology , Hippocampus/cytology , Naloxone/pharmacology , Narcotic Antagonists/pharmacology , Nifedipine/pharmacology , Patch-Clamp Techniques , Peptides/pharmacology , Pyramidal Cells/drug effects , Rats , Rats, Sprague-Dawley , Receptors, Opioid/agonists , Spider Venoms/pharmacology , omega-Agatoxin IVA , omega-Conotoxin GVIA , Nociceptin
16.
Neuroscience ; 75(2): 333-7, 1996 Nov.
Article in English | MEDLINE | ID: mdl-8930999

ABSTRACT

The heptadecapeptide orphanin FQ has recently been shown to be the endogenous agonist for the orphan opioid-like receptor, LC132. The molecular evidence that LC132 and orphanin FQ are evolutionarily related to other opioid receptors and their ligands suggests that these proteins may also play a role in modulating opiate actions. We now report that orphanin FQ (0.5-10 nmol), injected intracerebroventricularly in mice, does not produce hyperalgesia as suggested previously but rather reverses opioid-mediated (i.e. naloxone-sensitive) stress-induced antinociception in three different algesiometric assays. In addition to its antagonism of endogenous opioid antinociception, orphanin FQ dose-dependently (2.5-25 nmol) reverses systemic morphine antinociception (5 mg/kg, s.c.). Based on these data, we propose that orphanin FQ is a functional anti-opioid peptide.


Subject(s)
Narcotic Antagonists , Opioid Peptides/pharmacology , Acetates , Analgesics, Opioid/antagonists & inhibitors , Analgesics, Opioid/pharmacology , Animals , Dose-Response Relationship, Drug , Female , Hyperalgesia/chemically induced , Injections, Intraventricular , Male , Mice , Morphine/antagonists & inhibitors , Morphine/pharmacology , Opioid Peptides/administration & dosage , Pain Measurement , Stress, Psychological/complications , Nociceptin
17.
Neurochem Res ; 21(11): 1387-96, 1996 Nov.
Article in English | MEDLINE | ID: mdl-8947929

ABSTRACT

We examined the effects of intracerebroventricular (i.c.v.) administration of orphanin FQ (OFQ) on locomotor activity in rats. The rats were habituated to locomotor-testing boxes and then injected i.c.v. with OFQ (0 - 10 nmoles). Acute injections of OFQ produced dose-orderly reductions in horizontal locomotion and rearing activity. This suppression of motor activity was characterized by a disruption of balance and muscle control. Within minutes of i.c.v. injection of the higher doses of OFQ, the rats exhibited flaccid muscle tone. They each lay in an atypical posture, pressing the abdomen against the floor, and splaying the hindlimbs. When these rats locomoted, their gate was unsteady. They wobbled from side to side, and frequently fell over. Repeated daily injections of OFQ resulted in a rapid development of tolerance to the OFQ-induced suppression of locomotion and rearing activity. Tolerance to the observed impairments of motor control were also apparent. In the rats that were repeatedly treated with the highest dose (10 nmol) of OFQ, tolerance to the motoric effects was still apparent after 7 days without OFQ treatment.


Subject(s)
Cerebral Ventricles/physiology , Motor Activity/drug effects , Opioid Peptides/pharmacology , Receptors, Opioid/agonists , Analysis of Variance , Animals , Cerebral Ventricles/drug effects , Drug Administration Schedule , Drug Tolerance , Habituation, Psychophysiologic , Injections, Intraventricular , Male , Opioid Peptides/administration & dosage , Rats , Rats, Sprague-Dawley , Stereotyped Behavior/drug effects , Nociceptin
18.
Proc Natl Acad Sci U S A ; 93(16): 8677-82, 1996 Aug 06.
Article in English | MEDLINE | ID: mdl-8710930

ABSTRACT

The heptadecapeptide orphanin FQ (OFQ) is a recently discovered neuropeptide that exhibits structural features reminiscent of the opioid peptides and that is an endogenous ligand to a G protein-coupled receptor sequentially related to the opioid receptors. We have cloned both the human and rat cDNAs encoding the OFQ precursor proteins, to investigate whether the sequence relationships existing between the opioid and OFQ systems are also found at the polypeptide precursor level, in particular whether the OFQ precursor would encode several bioactive peptides as do the opioid precursors, and to study the regional distribution of OFQ sites of synthesis. The entire precursor protein displays structural homology to the opioid peptide precursors, especially preprodynorphin and preproenkephalin. The predicted amino acid sequence of the OFQ precursor contains a putative signal peptide and one copy of the OFQ sequence flanked by pairs of basic amino acid residues. Carboxyl-terminal to the OFQ sequence, the human and rat precursors contain a stretch of 28 amino acids that is 100% conserved and thus may encode novel bioactive peptides. Two peptides derived from this stretch were synthesized but were found to be unable to activate the OFQ receptor, suggesting that if they are produced in vivo, these peptides would likely recognize receptors different from the OFQ receptor. To begin analyzing the sites of OFQ mRNA synthesis, Northern analysis of human and rat tissues were carried out and showed that the OFQ precursor mRNA is mainly expressed in the brain. In situ hybridization of rat brain slices demonstrated a regional distribution pattern of the OFQ precursor mRNA, which is distinct from that of the opioid peptide precursors. These data confirm that the OFQ system differs from the opioid system at the molecular level, although the OFQ and opioid precursors may have arisen from a common ancestral gene.


Subject(s)
Neuropeptides/genetics , Opioid Peptides/genetics , Amino Acid Sequence , Animals , Base Sequence , CHO Cells , Central Nervous System/physiology , Cloning, Molecular , Cricetinae , DNA Primers/chemistry , DNA, Complementary/genetics , Gene Expression , Humans , Molecular Sequence Data , Protein Precursors/genetics , RNA, Messenger/genetics , Rats , Receptors, Opioid/physiology , Recombinant Proteins , Sequence Homology, Amino Acid , Nociceptin Receptor , Nociceptin
19.
Brain Res ; 727(1-2): 225-9, 1996 Jul 15.
Article in English | MEDLINE | ID: mdl-8842403

ABSTRACT

An unbiased conditioned place preference procedure was used to determine whether the newly-identified neuropeptide orphanin FQ produced motivational effects after intracerebroventricular microinjections. Microinjections of orphanin FQ (0.1-100 nmol) failed to produce conditioned place preference or aversion, but a pronounced motor impairment was observed during conditioning sessions with the two highest doses. Thus, it appears that orphanin FQ lacks motivational effects when administered at behaviourally active doses.


Subject(s)
Cerebral Ventricles/physiology , Conditioning, Operant/physiology , Opioid Peptides/pharmacology , Animals , Cerebral Ventricles/drug effects , Conditioning, Operant/drug effects , Dose-Response Relationship, Drug , Injections, Intraventricular , Male , Microinjections , Morphine/pharmacology , Motivation , Motor Activity/drug effects , Naloxone/pharmacology , Narcotic Antagonists , Opioid Peptides/administration & dosage , Rats , Rats, Sprague-Dawley , Nociceptin
20.
Brain Res ; 724(2): 238-45, 1996 Jun 17.
Article in English | MEDLINE | ID: mdl-8828574

ABSTRACT

Adrenomedullin (ADM) is a hypotensive peptide with structural homology, including a ring structure linked by a disulfide bridge, to calcitonin gene-related peptide (CGRP), calcitonin and amylin. ADM is predominantly synthesized in the adrenal medulla, but immunoreactive ADM has also been detected in the human brain. Here we have characterized ADM binding sites in cultured rat astrocytes using human [125I]ADM(1-52) as radioligand. Half-maximal inhibition of [125I]ADM(1-52) binding by intact rat ADM(1-50) amounted to 0.27 +/- 0.03 nM (n = 15). The related peptides rat alpha-CGRP, rat amylin and salmon calcitonin displaced [125I]ADM(1-52) at 85-, 148-, and > 4000-fold higher concentrations. Half-maximal stimulation of cAMP accumulation by rat ADM(1-50) was obtained with 1.00 +/- 0.12 nM (n = 16). Rat alpha-CGRP was 214-fold, and rat amylin and salmon calcitonin were > 1000-fold less potent. Concerning cAMP accumulation the results were indistinguishable in mouse neuroblastoma x rat glioma hybrid cells (NG108-15), but here rat alpha-CGRP was > 1000-fold less potent than rat ADM(1-50). Human ADM(22-52) and human CGRP-I(8-37), which lack the ring structure, failed to stimulate cAMP accumulation, but they antagonized rat ADM(1-50) stimulated cAMP accumulation with inhibitory constants of 365 +/- 93 nM and 92 +/- 2 nM In astrocytes, and 45 +/- 3 nM and 1300 +/- 500 nM in NG108-15 cells. Rat ADM(1-50) did not raise cytosolic free calcium concentrations in astrocytes and NG108-15 cells. In conclusion, we have identified novel ADM receptors coupled to cAMP formation in cultured rat astrocytes and NG108-15 cells. Different interactions with the homologous peptide CGRP as well as truncated receptor antagonists ADM(22-52) and CGRP(8-37) in rat astrocytes and neuroblastoma x glioma hybrid cells are consistent with ADM receptor isotypes in the brain.


Subject(s)
Astrocytes/metabolism , Brain Neoplasms/metabolism , GTP-Binding Proteins/metabolism , Glioma/metabolism , Membrane Proteins/metabolism , Neuroblastoma/metabolism , Receptors, Peptide , Animals , Calcium/metabolism , Cell Line , Cyclic AMP/metabolism , Fluorescent Antibody Technique, Indirect , Humans , Immunohistochemistry , Iodine Radioisotopes , Isotope Labeling , Mice , Microscopy, Phase-Contrast , Rats , Rats, Wistar , Receptors, Adrenomedullin , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...